Immunogenic properties of plant-derived recombinant smallpox vaccine candidate pB5

Vaccine ◽  
2008 ◽  
Vol 26 (43) ◽  
pp. 5535-5540 ◽  
Author(s):  
Carla Portocarrero ◽  
Karen Markley ◽  
Hilary Koprowski ◽  
Sergei Spitsin ◽  
Maxim Golovkin
Parasitology ◽  
2017 ◽  
Vol 144 (10) ◽  
pp. 1356-1364 ◽  
Author(s):  
MARWA H. EL-FAHAM ◽  
KATHERINE J. WHEATCROFT-FRANCKLOW ◽  
HELEN P. PRICE ◽  
JON R. SAYERS ◽  
MICHAEL J. DOENHOFF

SUMMARYThe Schistosoma mansoni cercarial elastase (SmCE) has previously been shown to be poorly immunogenic in mice. However, a minority of mice were able to produce antibodies against SmCE after multiple immunizations with crude preparations containing the enzyme. These mice were partially protected against challenge infections of S. mansoni. In the present study, we show that in contrast to the poor immunogenicity of the enzymatically active native form of SmCE derived from a crude preparation (cercarial transformation fluid), immunization of CBA/Ca mice with two enzymatically inactive forms, namely purified native SmCE or a recombinant SmCE fused to recombinant Schistosoma japonicum glutathione S-transferase (rSmCE-SjGST), after adsorption onto aluminum hydroxide adjuvant, induced specific anti-SmCE immunoglobulin G (IgG) in all mice within 2 weeks of the second immunization. The IgG antibody response to rSmCE-SjGST was mainly of the IgG1 subclass. These results suggest that inactive forms of the antigen could be used to obtain the optimum immunogenic effects as a vaccine candidate against schistosomiasis. Mice immunized with the rSmCE-SjGST on alum had smaller mean worm burdens and lower tissue egg counts when compared with adjuvant alone- and recombinant SjGST-injected controls. The native SmCE was antigenically cross-reactive with homologous enzymes of Schistosoma haematobium and Schistosoma margrebowiei.


2020 ◽  
Vol 17 (4) ◽  
pp. 333-341
Author(s):  
Seyed Akbar Arianzad ◽  
Mehdi Zeinoddini ◽  
Azam Haddadi ◽  
Shahram Nazarian ◽  
Reza Hasan Sajedi

Background: S. dysenteriaeis the causative agent of shigellosis, a severe form of bacillary dysentery and this infectious disease is still a health problem worldwide, especially in children. The most important proteins of the Shigellatype III secretion system are IpaB and IpaD, which attach to the intestinal epithelial cells and provide the possibility of invasion and disease. These two proteins with immunogenic properties can be a suitable target to design and manufacture subunit recombinant vaccines. Objective: The aim of this study is to design an immunogenic chimeric protein against IpaB and IpaD as a subunit vaccine candidate through an in silicostudy. Methods: Firstly, the immunogenic epitopes of amino acid sequences, physico-chemical parameters, and the allergenicity of the chimeric protein were determined. Then the tertiary structure and the potential ability of the chimeric protein were predicted and evaluated in terms of inducing B cells’ immune responses with effective epitopes. Finally, the optimization of the chimeric protein was examined as the index affecting the protein expression. Results: Data showed an instability index of 37.18 and a well-established predicted third structure for the chimeric protein, with a z-score of -6.11. Also, more than 99% of its amino acids were in the optimal range. Minimum energy for mRNA structure increased to -317.9 and the Codon Adaptive Index (CAI) rose to 88%. The designed protein had no IgE specific B cell epitopes. Conclusion: Overall, the results of this study show that the designed protein can be considered as an immunogen vaccine candidate against S. dysenteriae.


2016 ◽  
Vol 23 (7) ◽  
pp. 648-651 ◽  
Author(s):  
Dorothy I. Jones ◽  
Charles E. McGee ◽  
Christopher J. Sample ◽  
Gregory D. Sempowski ◽  
David J. Pickup ◽  
...  

Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.


Vaccine ◽  
2007 ◽  
Vol 25 (49) ◽  
pp. 8290-8297 ◽  
Author(s):  
Audrey Ferrier-Rembert ◽  
Robert Drillien ◽  
Bernard Meignier ◽  
Daniel Garin ◽  
Jean-Marc Crance

2008 ◽  
Vol 284 (13) ◽  
pp. 8738-8746 ◽  
Author(s):  
Alessandro Mascioni ◽  
Breagh E. Bentley ◽  
Rosaria Camarda ◽  
Deborah A. Dilts ◽  
Pamela Fink ◽  
...  

Vaccine ◽  
2010 ◽  
Vol 28 (5) ◽  
pp. 1209-1216 ◽  
Author(s):  
Alfred von Krempelhuber ◽  
Jens Vollmar ◽  
Rolf Pokorny ◽  
Petra Rapp ◽  
Niels Wulff ◽  
...  

Vaccine ◽  
2021 ◽  
Author(s):  
Heeji Lim ◽  
Hyun Ju In ◽  
You-Jin Kim ◽  
Sundong Jang ◽  
Yun Ha Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document